RT Journal
T1 FDa approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
JF JAMA
JO JAMA
YR 2009
FD August 26
VO 302
IS 8
SP 841
OP 841
DO 
UL http://dx.doi.org/
AB 
On December 4, 2008, the Food and Drug Administration (FDA) approved an expanded age indication for the tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) Boostrix (GlaxoSmithKline Biologicals, Rixensart, Belgium). Boostrix is now licensed for use in persons aged 10-64 years as a single-dose booster immunization; the vaccine initially was licensed for persons aged 10-18 years. This announcement summarizes the indications for use of Boostrix. Complete recommendations of the Advisory Committee on Immunization Practices (ACIP) for Tdap vaccines have been described previously.1,2,3